Werfen presented today its 2025 fiscal year results, reporting €2.131 billion in sales, levered on the strength of its underlying business and geographic diversification. Despite an atypical macroeconomic environment, the company’s fundamentals showcased high resilience, with 3.3% organic growth. This progress reflects the strong traction of its primary specialized diagnostic lines and the company's solid competitive position globally. 

The structural strength of Werfen’s business model enabled the company to navigate a global landscape marked by particularly complex macroeconomic and geopolitical challenges affecting the entire sector. In addition to currency fluctuations and the impact of tariffs, the industry faced a widespread adjustment within the In-Vitro Diagnostics (IVD) market in China. Excluding the temporary effect of the Asian market, Werfen’s organic sales grew by a notable 6%, with strong momentum in North America (+8%), Latin America (+10%), and EEMEA (+7%). 

Furthermore, most business lines continued to show favorable performance, supported by the commercial expansion of recent product launches and a robust consolidated base. Notably, following the divestment of the Medical Devices business in July 2024 after being considered as non-strategic, the company’s 2025 financial figures reflect exclusively In-Vitro Diagnostics activity, where Werfen will focus its efforts in the coming years. 

From an operational standpoint, Werfen maintained high profitability, achieving an EBITDA of €473 million. This result reflects the company’s ability to absorb geopolitical pressures while simultaneously protecting an ambitious global expansion and investment plan. Werfen has made an exceptional investment effort to secure its future growth. 

During the 2025 reported fiscal year, the company allocated €190 million to R&D, representing 9% of net sales and thus consolidating its technological leadership. Simultaneously, Werfen completed the expansion of its flagship technology center in Bedford (USA)—adding nearly 10,000 m² of R&D and manufacturing space—and finalized the move to a new logistics hub in Devens (USA), bolstering its industrial and innovation footprint to support future growth. 

"2025 marked a year of consolidating our growth. In the face of one of the most complex geopolitical environments in decades, we have proven the immense resilience of our core business," stated Alejandro Risso, CEO at Werfen. "We haven’t hit the brakes on our plans; on the contrary, we have continued to invest with a forward-looking vision. This operational strength places us in an excellent position to capture market growth and enhance cash generation in the years ahead." 

Regarding its financial position, Werfen ended 2025 with net financial debt of €1.661 billion, showing year-over-year stability. This figure reflects exceptional fiscal discipline in a year marked by significant capital expenditure and an adverse macroeconomic climate. 

“Our capital structure is exceptionally resilient. Throughout 2025, we have actively managed our debt, proactively extending our maturity profile through the issuance of a €500 million bond and maintaining our Investment Grade credit rating. The company’s financial policy remains unchanged and conservative: our primary commitment for 2026 is to continue deleveraging and maintaining ample operating liquidity to solidify the foundations for robust growth in the years ahead,” stated Javier Gómez, CFO at Werfen.